Immuneering (IMRX) Competitors $9.01 +0.94 (+11.65%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$9.10 +0.09 (+1.00%) As of 09/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. KALV, AKBA, DAWN, TNGX, IMTX, NRIX, OCS, NAGE, VALN, and GYREShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include KalVista Pharmaceuticals (KALV), Akebia Therapeutics (AKBA), Day One Biopharmaceuticals (DAWN), Tango Therapeutics (TNGX), Immatics (IMTX), Nurix Therapeutics (NRIX), Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors KalVista Pharmaceuticals Akebia Therapeutics Day One Biopharmaceuticals Tango Therapeutics Immatics Nurix Therapeutics Oculis Niagen Bioscience Valneva Gyre Therapeutics KalVista Pharmaceuticals (NASDAQ:KALV) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Do analysts prefer KALV or IMRX? KalVista Pharmaceuticals currently has a consensus target price of $26.43, indicating a potential upside of 90.41%. Immuneering has a consensus target price of $13.75, indicating a potential upside of 52.61%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Immuneering.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has preferable earnings & valuation, KALV or IMRX? Immuneering has higher revenue and earnings than KalVista Pharmaceuticals. Immuneering is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$183.44M-$3.94-3.52Immuneering$320K1,170.46-$61.04M-$1.89-4.77 Does the media prefer KALV or IMRX? In the previous week, KalVista Pharmaceuticals had 10 more articles in the media than Immuneering. MarketBeat recorded 15 mentions for KalVista Pharmaceuticals and 5 mentions for Immuneering. KalVista Pharmaceuticals' average media sentiment score of 0.37 beat Immuneering's score of 0.33 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in KALV or IMRX? 67.7% of Immuneering shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is KALV or IMRX more profitable? Immuneering's return on equity of -146.28% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -195.62% -89.96% Immuneering N/A -146.28%-117.22% Which has more risk and volatility, KALV or IMRX? KalVista Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. SummaryKalVista Pharmaceuticals beats Immuneering on 8 of the 15 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$335.47M$3.12B$5.78B$10.28BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-4.7721.3676.9426.98Price / Sales1,170.46475.60543.88128.54Price / CashN/A45.3237.1760.63Price / Book6.779.6913.836.37Net Income-$61.04M-$52.92M$3.29B$271.46M7 Day Performance6.12%2.19%1.57%2.53%1 Month Performance168.96%8.96%6.87%9.42%1 Year Performance272.31%10.84%81.59%30.16% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.3317 of 5 stars$9.01+11.6%$13.75+52.6%+295.2%$335.47M$320K-4.7760KALVKalVista Pharmaceuticals4.0419 of 5 stars$15.96+0.9%$26.29+64.7%+29.8%$796.38MN/A-4.33100AKBAAkebia Therapeutics3.8206 of 5 stars$3.13+5.7%$6.75+115.7%+119.3%$784.83M$160.18M-18.41430Positive NewsDAWNDay One Biopharmaceuticals3.05 of 5 stars$7.47-1.1%$25.29+238.5%-47.7%$773.36M$131.16M-7.8660Positive NewsTNGXTango Therapeutics2.1425 of 5 stars$6.81-1.9%$10.50+54.2%-5.0%$772.15M$42.07M-5.1290Insider TradeIMTXImmatics3.1276 of 5 stars$5.81-7.2%$14.67+152.4%-45.8%$760.90M$168.65M-8.94260News CoveragePositive NewsAnalyst ForecastNRIXNurix Therapeutics2.0684 of 5 stars$9.70-2.1%$29.07+199.7%-63.7%$757.61M$54.55M-3.72300Positive NewsOCSOculis3.2022 of 5 stars$17.25+0.2%$35.75+107.2%+45.6%$751.86MN/A-6.462NAGENiagen Bioscience2.0437 of 5 stars$9.45+0.4%$13.42+42.0%N/A$750.47M$99.60M45.00120VALNValneva2.9058 of 5 stars$8.52-1.5%$15.00+76.1%+64.2%$743.27M$183.52M-8.69700Gap DownGYREGyre Therapeutics1.6768 of 5 stars$7.89+2.6%$18.00+128.1%-44.6%$740.65M$105.76M789.7940Positive News Related Companies and Tools Related Companies KALV Alternatives AKBA Alternatives DAWN Alternatives TNGX Alternatives IMTX Alternatives NRIX Alternatives OCS Alternatives NAGE Alternatives VALN Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
